4-(三氟甲氧基)苯甲胺 | 93919-56-3

• 物质功能分类: 有机原料 - 氨基化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(三氟甲氧基)苯甲胺
• 中文别名: 4-(三氟甲氧基)苄胺；4-三氟甲氧基苄胺；对三氟甲氧基苄胺
• 英文名称: 4-(trifluoromethoxy)benzyl amine
• 英文别名: (4-(trifluoromethoxy)phenyl)methanamine；p-(trifluoromethoxy)benzylamine；1-(4-(trifluoromethoxy)-phenyl)methanamine；1-(4-(trifluoromethoxy)phenyl)ethan-1-amine；4-(Trifluoromethoxy)benzylamine；[4-(trifluoromethoxy)phenyl]methanamine
• CAS: 93919-56-3
• 化学式: C₈H₈F₃NO
• mdl: MFCD00061237
• 分子量: 191.153
• InChiKey: DBGROTRFYBSUTR-UHFFFAOYSA-N

物化性质

• 沸点：
  57-60 °C10 mm Hg(lit.)
• 密度：
  1.252 g/mL at 25 °C(lit.)
• 闪点：
  172 °F
• 稳定性/保质期：
  在常温常压下稳定，应避免与强氧化剂接触。

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险等级：
  8
• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2922199090
• 包装等级：
  III
• 危险类别：
  8
• 危险品运输编号：
  UN2735
• 危险性防范说明：
  P305+P351+P338
• 危险性描述：
  H227,H315,H319,H335
• 储存条件：
  密封保存于阴凉干燥的库房中，并远离氧化剂。

SDS

Name:	4-(Trifluoromethoxy)benzylamine 97+% (gc) Material Safety Data Sheet
Synonym:	4-(Aminomethyl)-alpha, alpha, alpha-trifluoromethoxybenzen
CAS:	93919-56-3

Section 1 - Chemical Product MSDS Name:4-(Trifluoromethoxy)benzylamine 97+% (gc) Material Safety Data Sheet
Synonym:4-(Aminomethyl)-alpha, alpha, alpha-trifluoromethoxybenzen

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
93919-56-3	4-(Trifluoromethoxy)benzylamine	97+	300-040-1

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation.
Ingestion:
The toxicological properties of this substance have not been fully investigated.
Inhalation:
Causes respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. Will burn if involved in a fire. Combustible liquid.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes. Use only in a chemical fume hood.
Storage:
Keep away from sources of ignition. Store in a cool, dry place.
Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 93919-56-3: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: clear, colorless
Odor: Amine odor.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 57 - 60 deg C @ 10.00mm Hg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: 77 deg C ( 170.60 deg F)
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density: 1.2520g/cm3
Molecular Formula: C8H8F3NO
Molecular Weight: 191.15

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stability unknown.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong acids - strong bases - strong oxidizing agents - strong reducing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide, hydrogen fluoride gas.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 93919-56-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-(Trifluoromethoxy)benzylamine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 93919-56-3: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 93919-56-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 93919-56-3 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(三氟甲氧基)苯甲胺 在 [RuHCl(CO)(PPh₃)₃] 、 potassium tert-butylate 作用下， 以 叔丁醇 为溶剂， 反应 12.0h， 以93%的产率得到4-(三氟甲氧基)苯甲酰胺
  参考文献：
  名称：

  高度选择性的钌催化的胺直接氧化成酰胺

  摘要：

  关于胺有氧氧化为酰胺的报道很少，而报道的那些则受到诸如收率或选择性差以及在高压下使用纯氧的局限性的困扰。本文中，我们报告了一种实用且有效的钌催化合成方案，该方案能够使用容易获得的试剂和环境空气作为唯一氧化剂，将多种伯脂肪族，杂环和苄基胺选择性氧化为它们相应的酰胺。相反，仲胺选择性地产生苯甲酰胺作为唯一产物。机理研究揭示了腈的中间体，腈经过水合后生成酰胺，作为最终产物。

  DOI：

  10.1002/chem.201705601
• 作为产物：
  描述：

  4-(trifluoromethoxy)benzaldehyde oxime 在 盐酸 、 锌 作用下， 以 乙醇 、 水 为溶剂， 反应 1.0h， 以71%的产率得到4-(三氟甲氧基)苯甲胺
  参考文献：
  名称：

  新型三唑-氨基酸杂种对念珠菌生长和毒力的影响：体内和体外研究†

  摘要：

  越来越多的人类念珠菌的发病率和倾向念珠菌物种成为现有化疗耐药是公认的健康问题。本研究表明，新型三唑-氨基酸杂种的成功合成具有针对念珠菌的强大的体外和体内抑制活性。特别地，化合物68和70显示出对氟康唑（FLC）抗性以及白色念珠菌敏感临床分离株的有效体外活性。铅抑制剂68和70的时间杀灭曲线分析显示出它们的抑菌性质。在68和70的存在下，水解酶（主要是蛋白酶和磷脂酶）的分泌显着减少，表明它们对真菌毒力的干扰。暴露于化合物68和70的念珠菌细胞的TEM分析清楚地表明，形态变化和细胞内损伤是其可能的作用方式。对两种最有效的抑制剂（68和70）进行了初步的机理研究。）显示出麦角固醇生物合成的抑制作用，从而导致细胞丧失其完整性和生存能力。所选择的化合物在HEK293细胞系中直至200μgmL -1的浓度都没有显示出明显的细胞毒性。一个在硅片的分析68和70结合到建模C.白色念珠菌小号CYP51表明临

  DOI：

  10.1039/c6ob01718e

文献信息

• Virtual Screening of Peptide and Peptidomimetic Fragments Targeted to Inhibit Bacterial Dithiol Oxidase DsbA
  作者：Wilko Duprez、Prabhakar Bachu、Martin J. Stoermer、Stephanie Tay、Róisín M. McMahon、David P. Fairlie、Jennifer L. Martin

  DOI：10.1371/journal.pone.0133805

  日期：——

  Antibacterial drugs with novel scaffolds and new mechanisms of action are desperately needed to address the growing problem of antibiotic resistance. The periplasmic oxidative folding system in Gram-negative bacteria represents a possible target for anti-virulence antibacterials. By targeting virulence rather than viability, development of resistance and side effects (through killing host native microbiota) might be minimized. Here, we undertook the design of peptidomimetic inhibitors targeting the interaction between the two key enzymes of oxidative folding, DsbA and DsbB, with the ultimate goal of preventing virulence factor assembly. Structures of DsbB - or peptides - complexed with DsbA revealed key interactions with the DsbA active site cysteine, and with a hydrophobic groove adjacent to the active site. The present work aimed to discover peptidomimetics that target the hydrophobic groove to generate non-covalent DsbA inhibitors. The previously reported structure of a Proteus mirabilis DsbA active site cysteine mutant, in a non-covalent complex with the heptapeptide PWATCDS, was used as an in silico template for virtual screening of a peptidomimetic fragment library. The highest scoring fragment compound and nine derivatives were synthesized and evaluated for DsbA binding and inhibition. These experiments discovered peptidomimetic fragments with inhibitory activity at millimolar concentrations. Although only weakly potent relative to larger covalent peptide inhibitors that interact through the active site cysteine, these fragments offer new opportunities as templates to build non-covalent inhibitors. The results suggest that non-covalent peptidomimetics may need to interact with sites beyond the hydrophobic groove in order to produce potent DsbA inhibitors.

  迫切需要具有新型骨架和新作用机制的抗菌药物来解决日益严重的抗生素抗药性问题。革兰氏阴性菌中的周质氧化折叠系统代表了抗毒力抗菌药物可能的靶点。通过针对毒力而非生存能力，可能最大限度地减少耐药性的发展和副作用（通过杀死宿主的原生微生物群）。在此，我们进行了设计，旨在针对氧化折叠的两个关键酶DsbA和DsbB之间的相互作用，设计出肽模拟物抑制剂，最终目标是阻止毒力因子组装。DsbB或肽与DsbA复合物的结构揭示了与DsbA活性位点半胱氨酸以及活性位点附近的一个疏水性凹槽的关键相互作用。目前的工作目标是发现靶向疏水性凹槽的肽模拟物，以生成非共价DsbA抑制剂。先前报道的变形杆菌DsbA活性位点半胱氨酸突变体的结构，在非共价复合物中与七肽PWATCDS结合，被用作计算机模拟筛选肽模拟物片段库的模板。得分最高的片段化合物及其九个衍生物被合成，并评估其DsbA结合和抑制作用。这些实验发现了在毫摩尔浓度下具有抑制活性的肽模拟物片段。尽管相对于通过活性位点半胱氨酸相互作用的大分子共价肽抑制剂而言，这些片段的效力较弱，但它们提供了作为构建非共价抑制剂模板的新机会。结果表明，非共价肽模拟物可能需要与疏水性凹槽以外的位点相互作用，才能产生强效的DsbA抑制剂。
• Pyrrolobenzodiazepine arylcarboxamides and derivatives thereof as follicle-stimulating hormone receptor antagonists
  申请人：Failli A. Amedeo

  公开号：US20060199806A1

  公开（公告）日：2006-09-07

  This invention provides pyrrolobenzodiazepine arylcarboxamides selected from those of Formula (1), which act as follicle stimulating hormone receptor antagonists, as well as pharmaceutical compositions and methods of treatment

  这项发明提供了从式（1）中选择的吡咯苯并二氮杂环芳基甲酰胺，其作为促卵泡生成激素受体拮抗剂，以及药物组合物和治疗方法。
• [EN] SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY<br/>[FR] COMPOSÉS SULFONAMIDES AYANT UNE ACTIVITÉ D'ANTAGONISTE DE TRPM8
  申请人：MITSUBISHI TANABE PHARMA CORP

  公开号：WO2012124825A1

  公开（公告）日：2012-09-20

  Sulfonamide compounds having TRPM8 antagonistic activity are provided. A sulfonamide compound of formula (I) or a pharmaceutically acceptable salt thereof, or a prodrug thereof: (I) wherein Ring A is bicyclic aromatic heterocycle comprised of (a) pyridine is condensed with benzene; or (b) pyridine is condensed with monocyclic aromatic heterocycle, and Ring A binds to a sulfonylamino moiety on a carbon atom adjacent to a nitrogen atom of the pyridine ring constituting Ring A, Ring B is (a) monocyclic or bicyclic aromatic hydrocarbon; (b) monocyclic or bicyclic alicyclic hydrocarbon; (c) monocyclic or bicyclic aromatic heterocycle; or (d) monocyclic or bicyclic non-aromatic heterocycle, Ring C is (a) benzene; or (b) monocyclic aromatic heterocycle, and other symbols are the same as defined in the specification.

  提供具有TRPM8拮抗活性的磺胺类化合物。公式（I）的磺胺类化合物或其药学上可接受的盐，或其前药：（I）其中环A是由（a）吡啶与苯环融合；或（b）吡啶与单环芳香杂环融合而成的双环芳香杂环，环A与构成环A的吡啶环上的氮原子相邻的碳原子上的磺酰氨基团结合，环B是（a）单环或双环芳香烃；（b）单环或双环脂环烃；（c）单环或双环芳香杂环；或（d）单环或双环非芳香杂环，环C是（a）苯环；或（b）单环芳香杂环，其他符号与规范中定义的相同。
• Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
  申请人：——

  公开号：US20040157849A1

  公开（公告）日：2004-08-12

  Compounds of formula (I) 1 are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

  式（I）的化合物是新颖的VR1拮抗剂，可用于治疗疼痛、炎症性热性过敏、尿失禁和膀胱过度活动。
• Parallel Solution-Phase Synthesis and General Biological Activity of a Uridine Antibiotic Analog Library
  作者：Omar Moukha-chafiq、Robert C. Reynolds

  DOI：10.1021/co4001452

  日期：2014.5.12

  coupling of the amino terminus of d-phenylalanine methyl ester to the free 5′-carboxylic acid moiety of 33 followed by sodium hydroxide treatment led to carboxylic acid analog 77. Hydrolysis of this material gave analog 78. The intermediate 77 served as the precursor for the preparation of novel dipeptidyl uridine analogs 79–99 through peptide coupling reactions to diverse amine reactants. None of the described

  在 NIH 路线图计划的中试规模库 (PSL) 计划下，以溶液相方式从胺2和羧酸33和77合成了一个包含 94 种尿苷抗生素类似物的小型库。多样醛，磺酰氯，和羧酸反应物套缩合，2，酸介导的水解导致后，向目标化合物3 - 32以良好的收率和高的纯度。同样，用不同的胺和磺胺处理33得到34 – 75。d氨基末端的偶联-苯丙氨酸甲酯到33的游离 5'-羧酸部分，然后用氢氧化钠处理产生羧酸类似物77。该材料的水解得到类似物78。中间77担任该前体为二肽基新颖尿苷类似物的制备79 - 99通过肽偶联到不同的胺反应剂反应。所描述的化合物均未显示出显着的抗癌或抗疟活性。通过 NIH MLPCN 计划提供和报告的初级筛选中的酶和受体，许多样品表现出各种有希望的抑制性、激动剂、拮抗剂或激活剂特性。